Structure Therapeutics Inc. (GPCR) — Financial statements
Income statement, balance sheet, and cash flow for Structure Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 225↑107.0% | 109↑55.2% | 70↑93.7% | 36↑24.3% | 29 | |
| General & Administrative Expenses | 62↑24.6% | 49↑51.2% | 33↑99.6% | 16↑90.7% | 9 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 62↑24.6% | 49↑51.2% | 33↑99.6% | 16↑90.7% | 9 | |
| Other Expenses | -3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 284↑79.3% | 158↑54.0% | 103↑95.5% | 53↑39.4% | 38 | |
| Total Costs & Expenses | 288↑81.7% | 158↑54.0% | 103↑95.5% | 53↑39.4% | 38 | |
| Operating Results | ||||||
| Operating Income | -288↓81.7% | -158↓54.0% | -103↓95.5% | -53↓39.4% | -38 | |
| Depreciation & Amortization | 4↑293.1% | 0.99↑236.3% | 0.30↑6.5% | 0.28↑284.7% | 0.07 | |
| EBITDA | -137↑13.0% | -157↓53.4% | -102↓96.0% | -52↓39.0% | -38 | |
| EBIT | -141↑11.1% | -158↓54.0% | -103↓95.5% | -53↓39.4% | -38 | |
| Interest & Other Income | ||||||
| Net Interest Income | 36↓0.1% | 36↑309454.9% | -0.01↓100.9% | 1↑1130.0% | -0.12 | |
| Interest Income | 36↓0.2% | 36↑169.3% | 13↑965.7% | 1↑1029003.3% | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 13 | 0.00↓100.0% | 0.12 | |
| Non-Operating Income | -147 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 147↑306.8% | 36↑168.9% | 13↑965.3% | 1↑1130.3% | -0.12 | |
| Income Before Tax | -141↓15.1% | -122↓36.7% | -89↓74.2% | -51↓35.7% | -38 | |
| Income Tax Expense | 0.52↑66.1% | 0.31↑31.4% | 0.24↑1288.2% | 0.02↓92.6% | 0.23 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -141↓15.2% | -123↓36.7% | -90↓74.6% | -51↓34.9% | -38 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -141↓15.2% | -123↓36.7% | -90↓74.6% | -51↓28.3% | -40 | |
| Bottom-Line Net Income | -141↓15.2% | -123↓36.7% | -90↓69.6% | -53↓20.7% | -44 | |
| EPS (Basic) | -2.40↓2.6% | -2.34↑3.7% | -2.43↓68.8% | -1.44↓20.0% | -1.20 | |
| EPS (Diluted) | -2.40↓2.6% | -2.34↑3.7% | -2.43↓68.8% | -1.44↓20.0% | -1.20 | |
| Weighted Average Shares | 59↑12.5% | 53↑43.3% | 37↑0.4% | 37↑0.0% | 37 | |
| Weighted Average Diluted Shares | 59↑12.5% | 53↑43.3% | 37↑0.4% | 37↑0.0% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.